Margaret Callahan

Hematology | Oncology

263 Farmington Ave
Farmington, CT 06030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 121 publications

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.

Journal: Journal for immunotherapy of cancer

Published: July 07, 2026

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.

Journal: Nature medicine

Published: September 12, 2025

Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules.

Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2025

Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.

Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.

Journal: Melanoma research

Published: June 25, 2025

The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

The response to anti-PD-1 and anti-LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming.

Journal: Science translational medicine

Published: April 09, 2025

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020.

Journal: Journal for immunotherapy of cancer

Published: December 02, 2024

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 06, 2024

Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysis.

Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysis.

Journal: Nature communications

Published: October 24, 2024

Decoding Spatial Tissue Architecture: A Scalable Bayesian Topic Model for Multiplexed Imaging Analysis.

Decoding Spatial Tissue Architecture: A Scalable Bayesian Topic Model for Multiplexed Imaging Analysis.

Journal: bioRxiv : the preprint server for biology

Published: October 17, 2024

Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma.

Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma.

Journal: Cell reports

Published: September 30, 2024

Spatial Immunophenotyping from Whole-Slide Multiplexed Tissue Imaging Using Convolutional Neural Networks.

Spatial Immunophenotyping from Whole-Slide Multiplexed Tissue Imaging Using Convolutional Neural Networks.

Journal: bioRxiv : the preprint server for biology

Published: September 04, 2024

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors.

Sarcoid-like reactions in patients treated with checkpoint inhibitors for advanced solid tumors.

Journal: The oncologist

Published: June 17, 2024

Showing 1-12 of 121

Last Updated: 09/26/2026